We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Roebuck Food Group Public Limited Company | LSE:RFG | London | Ordinary Share | IE0006447985 | ORD EUR0.025 (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 13.00 | 12.00 | 14.00 | 13.00 | 13.00 | 13.00 | 0.00 | 07:49:38 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Refrigerated Whse & Storage | 26.74M | -1.85M | -0.0373 | -3.49 | 6.46M |
TIDMRFG
RNS Number : 9960U
Roebuck Food Group PLC
31 March 2023
Chairman's Statement
Roebuck Food Group plc (AIM: RFG), is pleased to announce its results for the year ended 31 December 2022.
Group Financial Highlights - Continuing Operations
-- Group revenue increased by 29% to GBP31.4m (2021: GBP24.3m) -- Earnings per share of 0.5p on continuing operations (2021 : loss of 3.5p) -- Profit after tax from continuing operation of GBP0.2m ( 2021 : loss GBP1.1m) -- EBITDA of GBP0.5m from the Dairy division (2021 : GBP0.1m) -- EBITDA of GBP0.4m from the Sourcing division (2021: GBP0.3m)
Divisional Highlights- Continuing Operations
GBP'000 Sourcing Dairy 2022 2021 2022 2021 ----- ----- ----- ------ Revenue 29.9 23.3 1.5 1.0 ----- ----- ----- ------ EBITDA 0.4 0.3 0.5 0.1 ----- ----- ----- ------ Operating Profit/(loss) 0.4 0.3 0.3 (0.8) ----- ----- ----- ------ Operating Margin 1.3% 1.3% 20% (80%) ----- ----- ----- ------
Sourcing Division
Sales at our sourcing division increased by 28% in 2022, compared with the same period in 2021, from GBP23.3m to GBP29.9m. Operating profit improved from GBP0.3m to GBP0.4m.
Townview Foods Ltd, continues to execute its commercial strategy which centres on diversification of products and end-markets. Our core animal proteins business continues to deliver consistent revenue and profits with a low-risk trading model and diversification of product sourcing and end-markets. From a standing start in March 2022, we have grown our dairy ingredients trading business into a significant operation both in terms of revenues and profits and we are confident about its prospects in 2023. We are also developing capability in plant-based ingredients which will allow us to offer a full portfolio of ingredient solutions to our customers. Operating margins declined slightly in the period, mainly due to the investment in talent, ICT and marketing. Overall, we are confident that our commercial strategy will continue to deliver profitable growth in 2023.
As part of a strategic alignment with Townview Foods Ltd, Foro International Connections Ltd was rebranded to Townview Sourcing Ltd in May 2022.
Townview Sourcing sales increased by 57% from GBP2.1m in 2021 to GBP3.3m in 2022.
The strategic alignment between Townview Foods Ltd and Townview Sourcing Ltd companies will create cost saving efficiencies and allow Roebuck Food Group Plc to have continuing ease of access to the UK, Republic of Ireland and European markets.
Chairman's Statement (Continued)
Dairy Division
Our primary dairy operation, Cantwellscourt Farm Ltd, exceeded expectations in 2022 in revenue and profit terms, driven by record dairy prices and good delivery across its management KPIs. Milk production was down 3% whilst revenue from milk sales was up 43% year on year. This was partially offset by input cost inflation, particularly in feed and fertiliser; our pasture-based system gives us some protection from rising input prices.
We expect the average farmgate milk price in 2023 to weaken versus last year but to remain at a level which delivers above average returns.
Discontinued
Our subsidiary, Grass to Milk Company Ltd, exited the Chinese market in H1 2022 due to ongoing lockdowns, supply chain disruptions and cost inflation. China has proven a difficult market for a majority of overseas dairy companies over the past 24-months with an unprecedented shift toward domestic supply. Opportunities for A2 protein ingredients in other export markets have failed to materialise, due to high dairy commodity prices making it difficult to achieve firm commitments from customers and a lack of interest from processors to dedicate capacity towards A2 during the scale-up phase. At this juncture, we do not have any immediate commercial prospects, so we have reclassified the business as a discontinued activity. Accordingly, we have impaired the intangible asset of GBP0.7m. The total loss from discontinued operations recogonised during the year is GBP1.1m.
During the year we also incurred an additional amount of GBP0.3m in respect of the sale of the cold store business that was sold in 2021.
Strategic Review
Following the successful sale of the Cold Stores business, Roebuck Food Group PLC (RFG), formerly known as Norish PLC, returned GBP49.92m to shareholders at the end of 2021. Overall, we believe our core sourcing and dairy businesses are well placed to deliver profitable growth in 2023, notwithstanding an expected reversal of some pricing tailwinds from 2022. We continue to examine M&A opportunities, which can complement our existing businesses, which fulfil our criteria in terms of growth prospects, margins and returns. We remain focused on delivering shareholder value through efficient capital allocation.
Dividend
The board does not recommend the payment of a dividend.
On behalf of the board, I would like to thank the management team and staff for their commitment and contribution in 2022.
Ted O'Neill
31 March 2023
Financial Review
Sales
Total Group revenue from continuing operations increased by 29% to GBP31.4m (2021: GBP24.3m). Revenues in the sourcing division increased by 28% to GBP29.9m (2021: GBP23.3m). Revenues in the dairy division increased by 50% to GBP1.5m (2021: GBP1m)
Gross profit
Gross profit from continuing activities increased to GBP571k (2021: GBP199k).
Operating profit/(loss)
Operating profit from continuing activities increased to GBP0.3m (2021: loss GBP1m), after an impairment charge of GBPNil (2021: GBP0.9m relating to fixed assets).
Finance expense (net )
Net Finance expense increased to GBP0.12m (2021: GBP0.06m).
Loss from discontinued operations
Loss from discontinued operations GBP1.4m (2021: profit GBP39.1m). Current year loss is made up of GBP0.3m relating to residual cold store sale transaction costs and GBP1.1m from the discontinued operations of Grass to Milk.
Earnings per share
The basic adjusted earnings per share from continuing operations increased to 0.5p (2021: loss per share 3.5p).
Net Debt
The net debt position is GBP3.4m (2021: Net cash GBP1.4m). During the year we discharged GBP1.5m in respect of liabilities due in respect of the disposal of the cold store division in 2021.
Financial Review (Continued)
Dividend
The board does not recommend a payment of a dividend.
Treasury policy and management
The treasury function, which is managed centrally, handles all Group funding, debt, cash, working capital and foreign exchange exposures. Group treasury policy concentrates on the minimisation of risk in all of the above areas and is overseen and approved by the Board. Speculative positions are not taken .
Financial risk management
The Group's financial instruments comprise borrowings, cash, and various items, such as trade receivables, trade payables etc., that arise directly from its operations. The main purposes of the financial instruments not arising directly from operations is to raise finance for the Group's operations.
The Group may enter into derivative transactions such as interest rate swaps, caps or forward foreign currency transactions in order to minimise its risks. The purpose of such transactions is to manage the interest rate and currency risks arising from the Group's operations and its sources of finance.
The main risks arising from the Group's financial instruments are interest rate risk, liquidity risk, credit risk and foreign exchange risk. The Group's policies for managing each of these risks are summarised below.
Interest rate risk
The Group finances its operations through a mixture of retained profits, bank and other borrowings at both fixed and floating rates of interest and working capital. The Group determines the level of borrowings at fixed rates of interest having regard to current market rates and future trends. At the year-end there are GBP0.1m at a floating rate of 5.44%.
Liquidity risk
The Group is in a net debt position of GBP3.4m. This is made up of cash of GBP1.5m, Invoice financing of GBP3.7m, term loans of GBP0.1m and leases of GBP1.1m.
Credit risk
The Group's policy is to minimise exposure to credit risk by performing the appropriate customer due diligence and monitoring the exposure to credit risk.
Foreign exchange risk
The Group's policy is to manage foreign exchange risk which arises principally in the product sourcing division. The Group does this by mainly purchasing Euros and US dollars at a fixed rate forward for cross currency transactions and using this rate in establishing a selling price for its goods in order to maintain an acceptable margin.
Gerard Murphy
Finance Director
Consolidated STATEMENT OF COMPREHENSIVE INCOME
for the financial year ended 31 December 2022
Restated 2022 2021 GBP'000 GBP'000 Continuing operations Revenue 31,351 24,313 Cost of sales (30,780) (24,114) Gross profit 571 199 ----------- -------- Fair value gain on biological assets 182 161 Administrative expenses (417) (502) Property, plant and equipment impairment - (862) Operating profit/(loss)from continuing operations 336 (1,004) ----------- -------- Interest received 9 - Finance expenses - lease interest (28) (26)
Finance expenses - interest on bank loans (100) (36) Profit/(loss) on continuing activities before taxation 217 (1,066) ----------- -------- Income taxes - Corporation tax (40) (20) Income taxes - Deferred tax (21) 33 Profit/(loss) for the financial year from continuing operations 156 (1,053) (Loss)/profit for the financial year from discontinued operations (1,404) 39,120 (Loss)/profit for the financial year attributable to owners of the parent (1,248) 38,067 Other comprehensive income/(expense) 169 (355) ----------- -------- Total comprehensive income for the financial year attributable to owners of the parent (1,079) 37,712 =========== ======== CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME ---------------------------------------------------------------- for the financial year ended 31 December 2022 (continued) 2022 2021 Earnings/(loss) per share expressed in pence per share: From continuing operations - basic 0.5p (3.5)p - diluted 0.5p (3.5)p From discontinued operations - basic (4.7)p 130.1p - diluted (4.7)p 130.1p
Consolidated Statement of financial position
at 31 December 2022
2022 2021 GBP'000 GBP'000 Non-current assets Goodwill 2,338 2,338 Intangible assets - 665 Property, plant and equipment 2,162 2,014 Biological assets 884 762 5,384 5,779 ------- ------- Current assets Trade and other receivables 7,223 3,988 Inventories 316 97 Cash and cash equivalents 1,491 4,543 9,030 8,628 ------- ------- TOTAL ASSETS 14,414 14,407 ------- ------- Equity attributable to owners of the parent Share capital 564 564 Share premium account - - Other reserves (68) (237) Retained earnings 5,204 6,452 ------- ------- TOTAL EQUITY 5,700 6,779 ------- ------- Non-current liabilities Borrowings 1,016 794 Deferred tax 58 35 1,074 829 ------- ------- Current liabilities Trade and other payables 3,427 2,579 Liabilities - discontinued operations 298 1,869 Borrowings 3,915 2,351 7,640 6,799 ------- ------- TOTAL EQUITY AND LIABILITIES 14,414 14,407 ------- -------
Consolidated Statement of Changes in Equity
For the financial year ended 31 December 2022
Other Share Share Other Distributable Retained capital premium Reserves Reserve Earnings Total GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 -------- -------- -------- -------------- --------- ---------- At 1 January 2021 5,640 7,321 141 - 5,750 18,852 -------- -------- -------- -------------- --------- ---------- Profit for the financial year - - - - 38,067 38,067 Foreign exchange loss - - (355) - - (355) -------- -------- -------- -------------- --------- ---------- Total comprehensive income for the financial year - - (355) - 38,067 37,712 Equity dividends paid - - - - (510) (510) Capital redemption - - - (12,420) (37,497) (49,917) Gain on capital redemption in JSOP - - - - 642 642 Reduction in capital (5,076) (7,321) (23) 12,420 - - Transactions with owners (5,076) (7,321) (23) - (37,365) (49,785) At 31 December 2021 564 - (237) - 6,452 6,779 -------- -------- -------- -------------- --------- ---------- Loss for the financial year - - - - (1,248) (1,248) Foreign exchange gain - - 169 - - 169 -------- -------- -------- -------------- --------- ---------- Total comprehensive income for the financial year - - 169 - (1,248) (1,079) Equity dividends paid - - - - - - Transactions with - owners - - - - - At 31 December 2022 564 - (68) - 5,204 5,700 ======== ======== ======== ============== ========= ==========
Consolidated Cash Flow Statement
for the financial year ended 31 December Restated 2022 2022 2021 GBP'000 GBP'000 Cash flow from operating activities Profit/(loss) on continuing activities before taxation 217 (1,066) Gain on biological assets (182) (161) Loss on sale of biological assets 117 - Foreign exchange gain (201) (50) Loss on discontinued activities (1,404) (270) Finance expenses 128 62 Finance income (9) - Bad debt expense 41 13 Taxation charge (40) (5) Impairment - Intangible asset 665 860 Impairment - property, plant and equipment - 1,519 Depreciation - property, plant and equipment 191 1,699 Operating cash flows before changes in working capital (477) 2,601 Changes in working capital and provisions: (Increase) in inventories (218) (39) (Increase)/ decrease in trade and other receivables (3,223) 10 Decrease in current assets held for sale - 381 (Decrease)/ increase in current liabilities held for sale (1,571) 1,869 Increase/ (decrease) in payables 848 (554) Taxation paid (25) (205) Net cash (used)/ generated from operating activities (4,189) 1,462 ------- --------------- Cash flow from investing activities Investment in intangible assets - (986) Purchase of property, plant and equipment (62) (1,840) Proceeds on disposal of subsidiary - 55,160 Costs incurred on disposal of subsidiary - (3,533) Cash included in subsidiary disposed - (72) Sale of biological assets 149 127 Purchase of biological assets - (9) ------- --------------- Net cash generated from investing activities 87 48,847 ------- --------------- Cash flows from financing activities Dividends paid to shareholders - (510) Invoice finance utilised 1,649 1,016
Finance lease capital repayments (91) (1,390) JSOP capital redemption - 642 Share Capital Redemption - (49,917) Finance Lease advance - 616 Term loan repayments (31) (374) ------- --------------- Net cash generated/ (used) from financing activities 1,527 (49,917) ------- --------------- Net (decrease)/ increase in cash and cash equivalents (3,052) 2,993 ------- --------------- Cash and cash equivalents beginning of the financial year 4,543 1,550 Cash and cash equivalents end of the financial year 1,491 4,543 ------- ---------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FR XFLFXXXLBBBZ
(END) Dow Jones Newswires
March 31, 2023 09:13 ET (13:13 GMT)
1 Year Roebuck Food Group Public Chart |
1 Month Roebuck Food Group Public Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions